nach oben

Erschienen in:

18.12.2017 | Original Article

Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis

verfasst von: Rosa Elda Barbosa-Cobos, Gustavo Lugo-Zamudio, Javier Flores-Estrada, Lizbeth Teresa Becerril-Mendoza, Pedro Rodríguez-Henríquez, Rubén Torres-González, Mario Adán Moreno-Eutimio, Julian Ramirez-Bello, José Moreno

Erschienen in: Clinical Rheumatology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of the is study is to examine the role of serum substance P (SP) levels as a simple biomarker for rheumatoid arthritis (RA) disease activity, its correlation with other markers of disease activity, and with selected clinical parameters. The study comprised 90 RA patients and 24 healthy controls. RA activity was assessed by means of the disease activity 28-C-reactive protein (DAS28-CRP) index and ultrasound power Doppler (USPD) by the German ultrasound score based on seven joints. SP serum values were obtained by means of an ELISA commercial kit. Statistics were achieved by the Student’s t test and Spearman correlation analysis with Bonferroni correction. As a group, RA patients had significantly increased levels of SP compared with healthy controls (p < 0.0001). SP levels correlated with DAS28-CRP (r = 0.5050, p < 0.0001), number of tender joints (NTJ, r = 0.4668, p < 0.0001), number of swollen joints (NSJ, r = 0.4439, p < 0.0001), visual analogue scale (VAS, r = 0.5131, p < 0.0001). However, SP did not correlate with CRP levels (r = 0.0468, p = 0.6613), nor with the USPD (r = 0.1740, p = 0.1009). Elevated serum SP is a common feature of RA patients, which also appears to correlate with clinical measurements of disease activity and with subjective clinical data (NTJ and VAS). Thus, although SP is higher in RA patients with high disease activity, it also detects subtle RA disease activity even in patients in apparent remission, which suggests its usefulness for therapeutic decisions.

Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640–647. https://doi.org/10.1002/acr.21649 CrossRef

Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, Sattler H, Albrecht K, Kaufmann J, Becker K, Sorensen H, Meier L, Burmester GR, Schmidt WA (2009) Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum 61(9):1194–1201. https://doi.org/10.1002/art.24646 CrossRefPubMed

Bakker MF, Cavet G, Jacobs JW, Bijlsma JW, Haney DJ, Shen Y, Hesterberg LK, Smith DR, Centola M, van Roon JA, Lafeber FP, Welsing PM (2012) Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 71(10):1692–1697. https://doi.org/10.1136/annrheumdis-2011-200963 CrossRefPubMedPubMedCentral

Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, Turner M, Sutton C, Smith DR, Haney DJ, Chernoff D, Hesterberg LK, Carulli JP, Taylor PC, Shadick NA, Weinblatt ME, Curtis JR (2013) Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 8(4):e60635. https://doi.org/10.1371/journal.pone.0060635 CrossRefPubMedPubMedCentral

Colebatch AN, Edwards CJ, Ostergaard M, van der Heijde D, Balint PV, D'Agostino MA, Forslind K, Grassi W, Haavardsholm EA, Haugeberg G, Jurik AG, Landewe RB, Naredo E, O'Connor PJ, Ostendorf B, Potocki K, Schmidt WA, Smolen JS, Sokolovic S, Watt I, Conaghan PG (2013) EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72(6):804–814. https://doi.org/10.1136/annrheumdis-2012-203158 CrossRefPubMed

D'Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, Balint P, Moller I, Iagnocco A, Naredo E, Ostergaard M, Gaillez C, Le Bars M (2016) Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD open 2(1):e000237. https://doi.org/10.1136/rmdopen-2015-000237 CrossRefPubMedPubMedCentral

Douglas SD, Leeman SE (2011) Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci 1217(1):83–95. https://doi.org/10.1111/j.1749-6632.2010.05826.x CrossRefPubMed

Farheen K, Agarwal SK (2011) Assessment of disease activity and treatment outcomes in rheumatoid arthritis. Journal of managed care pharmacy : JMCP 17(9 Supp B):S09–S13. https://doi.org/10.18553/jmcp.2011.17.s9-b.S09 CrossRefPubMed

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63(3):573–586. https://doi.org/10.1002/art.30129 CrossRefPubMedPubMedCentral

10.

Gautam M, Prasoon P, Kumar R, Reeta KH, Kaler S, Ray SB (2016) Role of neurokinin type 1 receptor in nociception at the periphery and the spinal level in the rat. Spinal Cord 54(3):172–182. https://doi.org/10.1038/sc.2015.206 CrossRefPubMed

11.

Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S (2005) Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis research & therapy 7(3):R416–R426. https://doi.org/10.1186/ar1503 CrossRef

12.

Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F (1993) Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 32(1):31–35. https://doi.org/10.1093/rheumatology/32.1.31 CrossRefPubMed

13.

Hong HS, Son Y (2014) Substance P ameliorates collagen II-induced arthritis in mice via suppression of the inflammatory response. Biochem Biophys Res Commun 453(1):179–184. https://doi.org/10.1016/j.bbrc.2014.09.090 CrossRefPubMed

14.

Im HJ, Li X, Muddasani P, Kim GH, Davis F, Rangan J, Forsyth CB, Ellman M, Thonar EJ (2008) Basic fibroblast growth factor accelerates matrix degradation via a neuro-endocrine pathway in human adult articular chondrocytes. J Cell Physiol 215(2):452–463. https://doi.org/10.1002/jcp.21317 CrossRefPubMedPubMedCentral

15.

Kubanov AA, Katunina OR, Chikin VV (2015) Expression of neuropeptides, neurotrophins, and neurotransmitters in the skin of patients with atopic dermatitis and psoriasis. Bull Exp Biol Med 159(3):318–322. https://doi.org/10.1007/s10517-015-2951-4 CrossRefPubMed

16.

Leonard AV, Thornton E, Vink R (2013) Substance P as a mediator of neurogenic inflammation after balloon compression induced spinal cord injury. J Neurotrauma 30(21):1812–1823. https://doi.org/10.1089/neu.2013.2993 CrossRefPubMed

17.

Lisowska B, Lisowski A, Siewruk K (2015) Substance P and chronic pain in patients with chronic inflammation of connective tissue. PLoS One 10(10):e0139206. https://doi.org/10.1371/journal.pone.0139206 CrossRefPubMedPubMedCentral

18.

Lotz M, Carson DA, Vaughan JH (1987) Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science (New York, NY) 235(4791):893–895. https://doi.org/10.1126/science.2433770 CrossRef

19.

Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R (2016) Neuropeptide substance P and the immune response. Cellular and molecular life sciences : CMLS 73(22):4249–4264. https://doi.org/10.1007/s00018-016-2293-z CrossRefPubMedPubMedCentral

20.

Munoz M, Covenas R (2014) Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids 46(7):1727–1750. https://doi.org/10.1007/s00726-014-1736-9 CrossRefPubMed

21.

Naredo E, Wakefield RJ, Iagnocco A, Terslev L, Filippucci E, Gandjbakhch F, Aegerter P, Aydin S, Backhaus M, Balint PV, Bruyn GA, Collado P, Finzel S, Freeston JE, Gutierrez M, Joshua F, Jousse-Joulin S, Kane D, Keen HI, Moller I, Mandl P, Ohrndorf S, Pineda C, Schmidt WA, Szkudlarek M, Conaghan PG, D'Agostino MA (2011) The OMERACT ultrasound task force--status and perspectives. J Rheumatol 38(9):2063–2067. https://doi.org/10.3899/jrheum.110425 CrossRefPubMed

22.

O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201(2):167–180. https://doi.org/10.1002/jcp.20061 CrossRefPubMed

23.

Okamura Y, Mishima S, Kashiwakura JI, Sasaki-Sakamoto T, Toyoshima S, Kuroda K, Saito S, Tokuhashi Y, Okayama Y (2017) The dual regulation of substance P-mediated inflammation via human synovial mast cells in rheumatoid arthritis. Allergology international : official journal of the Japanese Society of Allergology. https://doi.org/10.1016/j.alit.2017.03.002

24.

Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, Arima K, Nakamura H, Yamasaki S, Ida H, Kawakami A, Ueki Y, Matsuoka N, Nakashima M, Mizokami A, Kawabe Y, Mine M, Fukuda T, Eguchi K (2011) Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol 21(3):244–250. https://doi.org/10.1007/s10165-010-0384-5 CrossRefPubMed

25.

Ramalho R, Soares R, Couto N, Moreira A (2011) Tachykinin receptors antagonism for asthma: a systematic review. BMC pulmonary medicine 11(1):41. https://doi.org/10.1186/1471-2466-11-41 CrossRefPubMedPubMedCentral

26.

Ramonda R, Oliviero F, Galozzi P, Frallonardo P, Lorenzin M, Ortolan A, Scanu A, Punzi L (2015) Molecular mechanisms of pain in crystal-induced arthritis. Best Pract Res Clin Rheumatol 29(1):98–110. https://doi.org/10.1016/j.berh.2015.04.025 CrossRefPubMed

27.

Sakai K, Matsuno H, Tsuji H, Tohyama M (1998) Substance P receptor (NK1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 27(2):135–141CrossRefPubMed

28.

Sloniecka M, Le Roux S, Zhou Q, Danielson P (2016) Substance P enhances keratocyte migration and neutrophil recruitment through interleukin-8. Mol Pharmacol 89(2):215–225. https://doi.org/10.1124/mol.115.101014 CrossRefPubMed

29.

Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509. https://doi.org/10.1136/annrheumdis-2013-204573 CrossRefPubMed

30.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15. https://doi.org/10.1136/annrheumdis-2015-207524 CrossRefPubMed

31.

Stangenberg L, Burzyn D, Binstadt BA, Weissleder R, Mahmood U, Benoist C, Mathis D (2014) Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature. Proc Natl Acad Sci U S A 111(31):11419–11424. https://doi.org/10.1073/pnas.1410854111 CrossRefPubMedPubMedCentral

32.

Tavano F, di Mola FF, Latiano A, Palmieri O, Bossa F, Valvano MR, Latiano T, Annese V, Andriulli A, di Sebastiano P (2012) Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn's & colitis 6(5):563–570. https://doi.org/10.1016/j.crohns.2011.11.004 CrossRef

33.

Terenzi R, Romano E, Manetti M, Peruzzi F, Nacci F, Matucci-Cerinic M, Guiducci S (2013) Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. Ann Rheum Dis 72(6):1107–1109. https://doi.org/10.1136/annrheumdis-2012-202846 CrossRefPubMed

34.

Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC (2016) Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 356(3):664–672. https://doi.org/10.1124/jpet.115.230060 CrossRefPubMedPubMedCentral

35.

Vatrella A, Montagnani S, Calabrese C, Parrella R, Pelaia G, Biscione GL, Corcione N, Marsico SA, Guerra G (2010) Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents 24(4):425–432PubMed

36.

Wang Q, Zhou X (2015) Associations of MICA polymorphisms with inflammatory rheumatic diseases. The open rheumatology journal 9(1):94–100. https://doi.org/10.2174/1874312901409010094 CrossRefPubMedPubMedCentral

37.

Weinstock JV (2015) Substance P and the regulation of inflammation in infections and inflammatory bowel disease. Acta physiologica (Oxford, England) 213(2):453–461. https://doi.org/10.1111/apha.12428 CrossRef

Titel: Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis
verfasst von: Rosa Elda Barbosa-Cobos
Gustavo Lugo-Zamudio
Javier Flores-Estrada
Lizbeth Teresa Becerril-Mendoza
Pedro Rodríguez-Henríquez
Rubén Torres-González
Mario Adán Moreno-Eutimio
Julian Ramirez-Bello
José Moreno
Publikationsdatum: 18.12.2017
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 4/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3929-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Operation bei Blasenkrebs/© anistidesign / Fotolia, Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Mann wird von Ärztin untersucht/© Tashi-Delek, Getty Images, iStock (Symbolbild mit Fotomodellen)

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease

Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis

First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study

Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment

Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?